02496.HK
Wuhan YZY Biopharma Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.80
+0.00%Oct 16, 2026, 08:34 UTC
Youzhiyou Biopharmaceutical announced that the first patient had been dosed in the China Phase I study of Y225, its biosimilar candidate for hemophilia A prophylaxis.
Sep 9, 2026, 14:17 UTC
Youzhiyou Biologics announced a private placement of 35.5924 million domestic shares at RMB 2.43 per share to subscribers Yuan Qian, Zhou Hongfeng, and Zhou Pengfei, with net proceeds of about RMB 83 million, and the shares will resume trading on September 10.
Source:Aug 28, 2026, 09:36 UTC
Youshiyou Biopharmaceutical reported interim results for the six months ended June 2026, with revenue of 33.143 million RMB, down 10.9% year-on-year, and a narrowed net loss of 6.26 million RMB compared to a loss of 58.834 million RMB in the same period last year.
Source: